Last reviewed · How we verify
GXHPC1
GXHPC1 is a stem cell therapy that aims to repair damaged tissues.
GXHPC1 is a stem cell therapy that aims to repair damaged tissues. Used for Treatment of various degenerative diseases.
At a glance
| Generic name | GXHPC1 |
|---|---|
| Also known as | hADSCs |
| Sponsor | Gwo Xi Stem Cell Applied Technology Co., Ltd. |
| Drug class | Stem cell therapy |
| Modality | Small molecule |
| Therapeutic area | Regenerative Medicine |
| Phase | Phase 2 |
Mechanism of action
GXHPC1 utilizes Gwo Xi Stem Cell Applied Technology Co., Ltd.'s proprietary stem cell technology to promote tissue repair and regeneration. This approach has shown promise in various preclinical studies, although more research is needed to fully understand its mechanisms and potential benefits.
Approved indications
- Treatment of various degenerative diseases
Common side effects
- Unknown
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GXHPC1 CI brief — competitive landscape report
- GXHPC1 updates RSS · CI watch RSS
- Gwo Xi Stem Cell Applied Technology Co., Ltd. portfolio CI